{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:08:26Z","timestamp":1784365706353,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtha.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:03:31Z","timestamp":1747220611000},"page":"498-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bleeding risk and performance of bleeding risk assessment models in patients with venous thromboembolism on anticoagulation: results from the prospective observational bleeding and assess long-term outcomes on health in patients with venous thromboembolism (BACH-VTE) study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-2000","authenticated-orcid":false,"given":"Timothy","family":"Hoberstorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Nopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Deinsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.05.005_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"Konstantinides","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.05.005_bib2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib3","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.05.005_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2020.12.031","article-title":"Prediction models for recurrence and bleeding in patients with venous thromboembolism: a systematic review and critical appraisal","volume":"199","author":"de Winter","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.05.005_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/a-1339-9987","article-title":"Bleeding risk assessment in patients with venous thromboembolism","volume":"41","author":"Nopp","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.05.005_bib6","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.05.005_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.005_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.005_bib11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.05.005_bib12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.005_bib16","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtha.2025.05.005_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Ru\u00edz\u2013Gim\u00e9nez","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.05.005_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007901","article-title":"Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment","volume":"7","author":"Brown","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.05.005_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/jth.12239","article-title":"The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study","volume":"11","author":"Poli","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1160\/TH14-01-0081","article-title":"Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study","volume":"112","author":"Riva","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib22","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1160\/TH-17-03-0162","article-title":"Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation","volume":"117","author":"Seiler","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"de Winter","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.05.005_bib24","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.jtha.2024.05.031","article-title":"Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE study","volume":"22","author":"Guman","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102464","article-title":"Functional limitations 3 and 12 months after venous thromboembolism: a cohort study","volume":"8","author":"Steiner","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102324","article-title":"Impact of thrombosis location on walking capacity: a cohort study of patients with acute deep vein thrombosis","volume":"8","author":"Steiner","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.11.006","article-title":"The post-VTE functional status scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study","volume":"221","author":"Steiner","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.05.005_bib28","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.jtha.2024.07.016","article-title":"Anxiety in patients with venous thromboembolism: quantification and risk factors in a prospective cohort study","volume":"22","author":"Steiner","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jtha.2025.05.005_bib30","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1182\/bloodadvances.2022007027","article-title":"Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism","volume":"6","author":"Wells","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.05.005_bib31","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/09332480.2019.1579578","article-title":"A second chance to get causal inference right: a classification of data science tasks","volume":"32","author":"Hern\u00e1n","year":"2019","journal-title":"Chance"},{"key":"10.1016\/j.jtha.2025.05.005_bib33","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib34","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1055\/s-0042-1757744","article-title":"On-treatment comparative effectiveness of vitamin k antagonists and direct oral anticoagulants in GARFIELD-VTE, and focus on cancer and renal disease","volume":"6","author":"Haas","year":"2022","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2025.05.005_bib35","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.05.005_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1183\/09031936.00040714","article-title":"Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review","volume":"45","author":"Klok","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtha.2025.05.005_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.thromres.2022.11.016","article-title":"36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE","volume":"222","author":"Turpie","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.05.005_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2017.07.029","article-title":"The role of heparin lead-in in the real-world management of acute venous thromboembolism: the PREFER in VTE registry","volume":"157","author":"Bauersachs","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.05.005_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/20420986211062965","article-title":"Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register","volume":"12","author":"Palareti","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jtha.2025.05.005_bib40","first-page":"1657","article-title":"Safety and efficacy of rivaroxaban for extended-phase anticoagulation of patients with unprovoked or recurrent venous thromboembolism: real-life data from the MAC project","volume":"12","author":"Bortoluzzi","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jtha.2025.05.005_bib41","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH16-10-0810","article-title":"External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism","volume":"117","author":"Klok","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00077-2018","article-title":"Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism","volume":"51","author":"Klok","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtha.2025.05.005_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijcard.2019.11.105","article-title":"Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study","volume":"301","author":"Vedovati","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jtha.2025.05.005_bib44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1160\/TH13-02-0132","article-title":"Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism","volume":"110","author":"Lecumberri","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.thromres.2013.07.017","article-title":"Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis","volume":"132","author":"Alotaibi","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.05.005_bib46","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1055\/s-0035-1564042","article-title":"Gender difference in efficacy and safety of nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation or venous thromboembolism: a systematic review and a meta-analysis of the literature","volume":"41","author":"Dentali","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2016.03.086","article-title":"Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials","volume":"212","author":"Loffredo","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jtha.2025.05.005_bib48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1160\/TH16-11-0874","article-title":"Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin","volume":"117","author":"Brekelmans","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.005_bib49","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jth.14226","article-title":"Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism","volume":"16","author":"Huisman","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:21:51Z","timestamp":1778224911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625003198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1538783625003198"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.005","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding risk and performance of bleeding risk assessment models in patients with venous thromboembolism on anticoagulation: results from the prospective observational bleeding and assess long-term outcomes on health in patients with venous thromboembolism (BACH-VTE) study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}